Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITATION neoadjuvant durvalumab + tremelimumab + gemcitabine/cisplatin for locally advanced cholangiocarcinoma
2023-000138-13Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: 12-month survival after surgery. Started Jan 2023; status: active.
02
Drugs
durvalumabtremelimumabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2023-000138-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000138-13.